Virtual Library

Start Your Search

Siam Khajarern

Author of

  • +

    P3.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 981)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.15-24 - Ramathibodi Lung Cancer Consortium (RLC) Model: Multidisciplinary Team Approach Improves Lung Cancer Patients’ Survival Outcome (ID 14396)

      12:00 - 13:30  |  Author(s): Siam Khajarern

      • Abstract
      • Slides


      Technologies for investigation, diagnosis, and treatment for lung cancer are advance to improve patients’ survival. Many investigations will be performed once the patients were suspected to have lung cancer. All processes sometime take a long time to complete investigations before starting the treatment which may affect treatment outcomes.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Ramathibodi Lung Cancer Consortium (RLC) was established in October 2014, aims to help the patients accessing all investigations and treatments faster by multidisciplinary team (MDT) approach and patient-center with one-stop service system. We conduct RLC meeting every 1st and 3rd Tuesday of the month. As of May 2017, 200 new lung cancer patients were solved all problems by RLC team. We collected and analyzed the data of lung cancer patients between 2 groups. The first group was the patient whom underwent RLC model (160 cases) and the second group was control group which was the patient whom diagnosed before establishing RLC (72 cases). Our primary endpoint was time from first visit to first treatment. Secondary endpoints were time from first visit to first interventions, number visits from first visit to first treatment, and overall survival (OS). We also did subgroups analysis for time from first visit to first biopsy, to first imaging study, to surgery, to chemotherapy, and to radiation.

      4c3880bb027f159e801041b1021e88e8 Result

      Median time from first visit to first treatment was significantly decreased in RLC group (14 days) compared to 57 days in control group with HR of 2.86 (95% CI; 2.11-3.87, P<0.001). Median time from first visit to first intervention was also significantly decreased in RLC group (2 days) compared to 11 days in control group with HR of 2.01 (95% CI; 1.53-2.62, P<0.001). Median number of hospital visits was significantly lower in RLC group (1 visits) compared to control group (8 visits). All subgroup analyses showed significantly decreased duration of each investigation and each treatment in RLC group. In survival analysis, lung cancer patients whom underwent RLC model had significantly longer mOS compared to control group, especially in stage 3 and 4 disease [mOS = 2.4 vs 0.8 years, HR=0.42 (95% CI; 0.3-0.7, P<0.001)].

      8eea62084ca7e541d918e823422bd82e Conclusion

      RLC model is a very useful model helping lung cancer patients to access treatment and investigations in short period of time and translate to have significantly longer survival. RLC model also provides the cooperation in lung cancer research. This model should be applied for all cancers treatment. Working as MDT is the utmost importance for cancer treatment.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.